APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nonerosive Reflux Disease Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Nonerosive Reflux Disease Treatment Market Analysis and Forecast 2026-2032

19 December 2025195 pages

Choose your research edition.

Industry ResearchNonerosive Reflux Disease Treatment Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Nonerosive Reflux Disease Treatment Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Nonerosive Reflux Disease Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nonerosive Reflux Disease Treatment Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Nonerosive Reflux Disease Treatment Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Nonerosive Reflux Disease Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Nonerosive Reflux Disease Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Nonerosive Reflux Disease Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Nonerosive Reflux Disease Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Nonerosive Reflux Disease Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Nonerosive Reflux Disease Treatment include Takeda Pharmaceutical, Eisai, Johnson & Johnson, GlaxoSmithKline, AstraZeneca, SRS Pharmaceuticals, SFJ Pharmaceuticals Group, Ironwood Pharmaceuticals and Daewoong Pharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Nonerosive Reflux Disease Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Nonerosive Reflux Disease Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Nonerosive Reflux Disease Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Nonerosive Reflux Disease Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Nonerosive Reflux Disease Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Nonerosive Reflux Disease Treatment revenue, projected growth trends, production technology, application and end-user industry.

Nonerosive Reflux Disease Treatment Segment by Company

Takeda Pharmaceutical

Eisai

Johnson & Johnson

GlaxoSmithKline

AstraZeneca

SRS Pharmaceuticals

SFJ Pharmaceuticals Group

Ironwood Pharmaceuticals

Daewoong Pharmaceutical

Nonerosive Reflux Disease Treatment Segment by Type

H2 Receptor Antagonists

Antacids

Proton pump inhibitors

Others

Nonerosive Reflux Disease Treatment Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Nonerosive Reflux Disease Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nonerosive Reflux Disease Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nonerosive Reflux Disease Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nonerosive Reflux Disease Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Nonerosive Reflux Disease Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Nonerosive Reflux Disease Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nonerosive Reflux Disease Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Nonerosive Reflux Disease Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. H2 Receptor Antagonists Major Player Table 3. Antacids Major Player Table 4. Proton pump inhibitors Major Player Table 5. Others Major Player Table 6. Global Nonerosive Reflux Disease Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Pharmacies Major Player Table 8. Online Pharmacies Major Player Table 9. Retail Pharmacies Major Player Table 10. Nonerosive Reflux Disease Treatment Industry Trends Table 11. Nonerosive Reflux Disease Treatment Industry Drivers Table 12. Nonerosive Reflux Disease Treatment Industry Opportunities and Challenges Table 13. Nonerosive Reflux Disease Treatment Industry Restraints Table 14. Global Nonerosive Reflux Disease Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Nonerosive Reflux Disease Treatment Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Nonerosive Reflux Disease Treatment Market Share by Region (2021-2026) Table 17. Global Nonerosive Reflux Disease Treatment Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Nonerosive Reflux Disease Treatment Market Share by Region (2027-2032) Table 19. Global Nonerosive Reflux Disease Treatment Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Nonerosive Reflux Disease Treatment Revenue Market Share by Players (2021-2026) Table 21. Global Nonerosive Reflux Disease Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Nonerosive Reflux Disease Treatment Key Players Headquarters & Area Served Table 23. Global Nonerosive Reflux Disease Treatment Players, Product Type & Application Table 24. Global Nonerosive Reflux Disease Treatment Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Nonerosive Reflux Disease Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Nonerosive Reflux Disease Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Nonerosive Reflux Disease Treatment Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Nonerosive Reflux Disease Treatment Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Nonerosive Reflux Disease Treatment Revenue Market Share by Type (2021-2026) Table 31. Global Nonerosive Reflux Disease Treatment Revenue Market Share by Type (2027-2032) Table 32. Global Nonerosive Reflux Disease Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Nonerosive Reflux Disease Treatment Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Nonerosive Reflux Disease Treatment Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Nonerosive Reflux Disease Treatment Revenue Market Share by Application (2021-2026) Table 36. Global Nonerosive Reflux Disease Treatment Revenue Market Share by Application (2027-2032) Table 37. Takeda Pharmaceutical Company Information Table 38. Takeda Pharmaceutical Business Overview Table 39. Takeda Pharmaceutical Nonerosive Reflux Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Takeda Pharmaceutical Nonerosive Reflux Disease Treatment Product Portfolio Table 41. Takeda Pharmaceutical Recent Development Table 42. Eisai Company Information Table 43. Eisai Business Overview Table 44. Eisai Nonerosive Reflux Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Eisai Nonerosive Reflux Disease Treatment Product Portfolio Table 46. Eisai Recent Development Table 47. Johnson & Johnson Company Information Table 48. Johnson & Johnson Business Overview Table 49. Johnson & Johnson Nonerosive Reflux Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Johnson & Johnson Nonerosive Reflux Disease Treatment Product Portfolio Table 51. Johnson & Johnson Recent Development Table 52. GlaxoSmithKline Company Information Table 53. GlaxoSmithKline Business Overview Table 54. GlaxoSmithKline Nonerosive Reflux Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. GlaxoSmithKline Nonerosive Reflux Disease Treatment Product Portfolio Table 56. GlaxoSmithKline Recent Development Table 57. AstraZeneca Company Information Table 58. AstraZeneca Business Overview Table 59. AstraZeneca Nonerosive Reflux Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. AstraZeneca Nonerosive Reflux Disease Treatment Product Portfolio Table 61. AstraZeneca Recent Development Table 62. SRS Pharmaceuticals Company Information Table 63. SRS Pharmaceuticals Business Overview Table 64. SRS Pharmaceuticals Nonerosive Reflux Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. SRS Pharmaceuticals Nonerosive Reflux Disease Treatment Product Portfolio Table 66. SRS Pharmaceuticals Recent Development Table 67. SFJ Pharmaceuticals Group Company Information Table 68. SFJ Pharmaceuticals Group Business Overview Table 69. SFJ Pharmaceuticals Group Nonerosive Reflux Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. SFJ Pharmaceuticals Group Nonerosive Reflux Disease Treatment Product Portfolio Table 71. SFJ Pharmaceuticals Group Recent Development Table 72. Ironwood Pharmaceuticals Company Information Table 73. Ironwood Pharmaceuticals Business Overview Table 74. Ironwood Pharmaceuticals Nonerosive Reflux Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Ironwood Pharmaceuticals Nonerosive Reflux Disease Treatment Product Portfolio Table 76. Ironwood Pharmaceuticals Recent Development Table 77. Daewoong Pharmaceutical Company Information Table 78. Daewoong Pharmaceutical Business Overview Table 79. Daewoong Pharmaceutical Nonerosive Reflux Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Daewoong Pharmaceutical Nonerosive Reflux Disease Treatment Product Portfolio Table 81. Daewoong Pharmaceutical Recent Development Table 82. North America Nonerosive Reflux Disease Treatment Revenue by Type (2021-2026) & (US$ Million) Table 83. North America Nonerosive Reflux Disease Treatment Revenue by Type (2027-2032) & (US$ Million) Table 84. North America Nonerosive Reflux Disease Treatment Revenue by Application (2021-2026) & (US$ Million) Table 85. North America Nonerosive Reflux Disease Treatment Revenue by Application (2027-2032) & (US$ Million) Table 86. North America Nonerosive Reflux Disease Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 87. North America Nonerosive Reflux Disease Treatment Revenue by Country (2021-2026) & (US$ Million) Table 88. North America Nonerosive Reflux Disease Treatment Revenue by Country (US$ Million) & (2027-2032) Table 89. Europe Nonerosive Reflux Disease Treatment Revenue by Type (2021-2026) & (US$ Million) Table 90. Europe Nonerosive Reflux Disease Treatment Revenue by Type (2027-2032) & (US$ Million) Table 91. Europe Nonerosive Reflux Disease Treatment Revenue by Application (2021-2026) & (US$ Million) Table 92. Europe Nonerosive Reflux Disease Treatment Revenue by Application (2027-2032) & (US$ Million) Table 93. Europe Nonerosive Reflux Disease Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 94. Europe Nonerosive Reflux Disease Treatment Revenue by Country (2021-2026) & (US$ Million) Table 95. Europe Nonerosive Reflux Disease Treatment Revenue by Country (US$ Million) & (2027-2032) Table 96. China Nonerosive Reflux Disease Treatment Revenue by Type (2021-2026) & (US$ Million) Table 97. China Nonerosive Reflux Disease Treatment Revenue by Type (2027-2032) & (US$ Million) Table 98. China Nonerosive Reflux Disease Treatment Revenue by Application (2021-2026) & (US$ Million) Table 99. China Nonerosive Reflux Disease Treatment Revenue by Application (2027-2032) & (US$ Million) Table 100. Asia Nonerosive Reflux Disease Treatment Revenue by Type (2021-2026) & (US$ Million) Table 101. Asia Nonerosive Reflux Disease Treatment Revenue by Type (2027-2032) & (US$ Million) Table 102. Asia Nonerosive Reflux Disease Treatment Revenue by Application (2021-2026) & (US$ Million) Table 103. Asia Nonerosive Reflux Disease Treatment Revenue by Application (2027-2032) & (US$ Million) Table 104. Asia Nonerosive Reflux Disease Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 105. Asia Nonerosive Reflux Disease Treatment Revenue by Region (US$ Million) & (2021-2026) Table 106. Asia Nonerosive Reflux Disease Treatment Revenue by Region (US$ Million) & (2027-2032) Table 107. SAMEA Nonerosive Reflux Disease Treatment Revenue by Type (2021-2026) & (US$ Million) Table 108. SAMEA Nonerosive Reflux Disease Treatment Revenue by Type (2027-2032) & (US$ Million) Table 109. SAMEA Nonerosive Reflux Disease Treatment Revenue by Application (2021-2026) & (US$ Million) Table 110. SAMEA Nonerosive Reflux Disease Treatment Revenue by Application (2027-2032) & (US$ Million) Table 111. SAMEA Nonerosive Reflux Disease Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 112. SAMEA Nonerosive Reflux Disease Treatment Revenue by Country (2021-2026) & (US$ Million) Table 113. SAMEA Nonerosive Reflux Disease Treatment Revenue by Country (US$ Million) & (2027-2032) Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. Nonerosive Reflux Disease Treatment Image Figure 2. Global Nonerosive Reflux Disease Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nonerosive Reflux Disease Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. H2 Receptor Antagonists Image Figure 5. Antacids Image Figure 6. Proton pump inhibitors Image Figure 7. Others Image Figure 8. Global Nonerosive Reflux Disease Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Nonerosive Reflux Disease Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Pharmacies Image Figure 11. Online Pharmacies Image Figure 12. Retail Pharmacies Image Figure 13. Global Nonerosive Reflux Disease Treatment Market Size (US$ Million) & (2021-2032) Figure 14. Global Nonerosive Reflux Disease Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Nonerosive Reflux Disease Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Nonerosive Reflux Disease Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Nonerosive Reflux Disease Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Nonerosive Reflux Disease Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Nonerosive Reflux Disease Treatment Revenue Market Share by Type (2021-2032) Figure 21. Global Nonerosive Reflux Disease Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Nonerosive Reflux Disease Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Nonerosive Reflux Disease Treatment Revenue Market Share by Application (2021-2032) Figure 24. North America Nonerosive Reflux Disease Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Nonerosive Reflux Disease Treatment Revenue Share by Type (2021-2032) Figure 26. North America Nonerosive Reflux Disease Treatment Revenue Share by Application (2021-2032) Figure 27. North America Nonerosive Reflux Disease Treatment Revenue Share by Country (2021-2032) Figure 28. United States Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Nonerosive Reflux Disease Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Nonerosive Reflux Disease Treatment Revenue Share by Type (2021-2032) Figure 33. Europe Nonerosive Reflux Disease Treatment Revenue Share by Application (2021-2032) Figure 34. Europe Nonerosive Reflux Disease Treatment Revenue Share by Country (2021-2032) Figure 35. Germany Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Nonerosive Reflux Disease Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Nonerosive Reflux Disease Treatment Revenue Share by Type (2021-2032) Figure 45. China Nonerosive Reflux Disease Treatment Revenue Share by Application (2021-2032) Figure 46. Asia Nonerosive Reflux Disease Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Nonerosive Reflux Disease Treatment Revenue Share by Type (2021-2032) Figure 48. Asia Nonerosive Reflux Disease Treatment Revenue Share by Application (2021-2032) Figure 49. Asia Nonerosive Reflux Disease Treatment Revenue Share by Region (2021-2032) Figure 50. Japan Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Nonerosive Reflux Disease Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Nonerosive Reflux Disease Treatment Revenue Share by Type (2021-2032) Figure 58. SAMEA Nonerosive Reflux Disease Treatment Revenue Share by Application (2021-2032) Figure 59. SAMEA Nonerosive Reflux Disease Treatment Revenue Share by Country (2021-2032) Figure 60. Brazil Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Nonerosive Reflux Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • H2 Receptor Antagonists
  • Antacids
  • Proton pump inhibitors
  • Others
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Takeda Pharmaceutical
  • Eisai
  • Johnson & Johnson
  • GlaxoSmithKline
  • AstraZeneca
  • SRS Pharmaceuticals
  • SFJ Pharmaceuticals Group
  • Ironwood Pharmaceuticals
  • Daewoong Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Nonerosive Reflux Disease Treatment Market by Type
  3. 1.2.1 Global Nonerosive Reflux Disease Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 H2 Receptor Antagonists
  5. 1.2.3 Antacids
  6. 1.2.4 Proton pump inhibitors
  7. 1.2.5 Others
  8. 1.3 Nonerosive Reflux Disease Treatment Market by Application
  9. 1.3.1 Global Nonerosive Reflux Disease Treatment Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital Pharmacies
  11. 1.3.3 Online Pharmacies
  12. 1.3.4 Retail Pharmacies
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Nonerosive Reflux Disease Treatment Market Dynamics
  1. 2.1 Nonerosive Reflux Disease Treatment Industry Trends
  2. 2.2 Nonerosive Reflux Disease Treatment Industry Drivers
  3. 2.3 Nonerosive Reflux Disease Treatment Industry Opportunities and Challenges
  4. 2.4 Nonerosive Reflux Disease Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Nonerosive Reflux Disease Treatment Market Perspective (2021-2032)
  2. 3.2 Global Nonerosive Reflux Disease Treatment Growth Trends by Region
  3. 3.2.1 Global Nonerosive Reflux Disease Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Nonerosive Reflux Disease Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Nonerosive Reflux Disease Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Nonerosive Reflux Disease Treatment Revenue by Players
  2. 4.1.1 Global Nonerosive Reflux Disease Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Nonerosive Reflux Disease Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Nonerosive Reflux Disease Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Nonerosive Reflux Disease Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Nonerosive Reflux Disease Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Nonerosive Reflux Disease Treatment Players, Product Type & Application
  8. 4.5 Global Nonerosive Reflux Disease Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Nonerosive Reflux Disease Treatment Market CR5 and HHI
  11. 4.6.3 2025 Nonerosive Reflux Disease Treatment Tier 1, Tier 2, and Tier 3
5 Nonerosive Reflux Disease Treatment Market Size by Type
  1. 5.1 Global Nonerosive Reflux Disease Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Nonerosive Reflux Disease Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Nonerosive Reflux Disease Treatment Revenue Market Share by Type (2021-2032)
6 Nonerosive Reflux Disease Treatment Market Size by Application
  1. 6.1 Global Nonerosive Reflux Disease Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Nonerosive Reflux Disease Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Nonerosive Reflux Disease Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda Pharmaceutical
  2. 7.1.1 Takeda Pharmaceutical Company Information
  3. 7.1.2 Takeda Pharmaceutical Business Overview
  4. 7.1.3 Takeda Pharmaceutical Nonerosive Reflux Disease Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Pharmaceutical Nonerosive Reflux Disease Treatment Product Portfolio
  6. 7.1.5 Takeda Pharmaceutical Recent Developments
  7. 7.2 Eisai
  8. 7.2.1 Eisai Company Information
  9. 7.2.2 Eisai Business Overview
  10. 7.2.3 Eisai Nonerosive Reflux Disease Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Eisai Nonerosive Reflux Disease Treatment Product Portfolio
  12. 7.2.5 Eisai Recent Developments
  13. 7.3 Johnson & Johnson
  14. 7.3.1 Johnson & Johnson Company Information
  15. 7.3.2 Johnson & Johnson Business Overview
  16. 7.3.3 Johnson & Johnson Nonerosive Reflux Disease Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Johnson & Johnson Nonerosive Reflux Disease Treatment Product Portfolio
  18. 7.3.5 Johnson & Johnson Recent Developments
  19. 7.4 GlaxoSmithKline
  20. 7.4.1 GlaxoSmithKline Company Information
  21. 7.4.2 GlaxoSmithKline Business Overview
  22. 7.4.3 GlaxoSmithKline Nonerosive Reflux Disease Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 GlaxoSmithKline Nonerosive Reflux Disease Treatment Product Portfolio
  24. 7.4.5 GlaxoSmithKline Recent Developments
  25. 7.5 AstraZeneca
  26. 7.5.1 AstraZeneca Company Information
  27. 7.5.2 AstraZeneca Business Overview
  28. 7.5.3 AstraZeneca Nonerosive Reflux Disease Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 AstraZeneca Nonerosive Reflux Disease Treatment Product Portfolio
  30. 7.5.5 AstraZeneca Recent Developments
  31. 7.6 SRS Pharmaceuticals
  32. 7.6.1 SRS Pharmaceuticals Company Information
  33. 7.6.2 SRS Pharmaceuticals Business Overview
  34. 7.6.3 SRS Pharmaceuticals Nonerosive Reflux Disease Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 SRS Pharmaceuticals Nonerosive Reflux Disease Treatment Product Portfolio
  36. 7.6.5 SRS Pharmaceuticals Recent Developments
  37. 7.7 SFJ Pharmaceuticals Group
  38. 7.7.1 SFJ Pharmaceuticals Group Company Information
  39. 7.7.2 SFJ Pharmaceuticals Group Business Overview
  40. 7.7.3 SFJ Pharmaceuticals Group Nonerosive Reflux Disease Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 SFJ Pharmaceuticals Group Nonerosive Reflux Disease Treatment Product Portfolio
  42. 7.7.5 SFJ Pharmaceuticals Group Recent Developments
  43. 7.8 Ironwood Pharmaceuticals
  44. 7.8.1 Ironwood Pharmaceuticals Company Information
  45. 7.8.2 Ironwood Pharmaceuticals Business Overview
  46. 7.8.3 Ironwood Pharmaceuticals Nonerosive Reflux Disease Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Ironwood Pharmaceuticals Nonerosive Reflux Disease Treatment Product Portfolio
  48. 7.8.5 Ironwood Pharmaceuticals Recent Developments
  49. 7.9 Daewoong Pharmaceutical
  50. 7.9.1 Daewoong Pharmaceutical Company Information
  51. 7.9.2 Daewoong Pharmaceutical Business Overview
  52. 7.9.3 Daewoong Pharmaceutical Nonerosive Reflux Disease Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Daewoong Pharmaceutical Nonerosive Reflux Disease Treatment Product Portfolio
  54. 7.9.5 Daewoong Pharmaceutical Recent Developments
8 North America
  1. 8.1 North America Nonerosive Reflux Disease Treatment Revenue (2021-2032)
  2. 8.2 North America Nonerosive Reflux Disease Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Nonerosive Reflux Disease Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Nonerosive Reflux Disease Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Nonerosive Reflux Disease Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Nonerosive Reflux Disease Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Nonerosive Reflux Disease Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Nonerosive Reflux Disease Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Nonerosive Reflux Disease Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Nonerosive Reflux Disease Treatment Revenue by Country
  11. 8.6.1 North America Nonerosive Reflux Disease Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Nonerosive Reflux Disease Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Nonerosive Reflux Disease Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Nonerosive Reflux Disease Treatment Revenue (2021-2032)
  2. 9.2 Europe Nonerosive Reflux Disease Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Nonerosive Reflux Disease Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Nonerosive Reflux Disease Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Nonerosive Reflux Disease Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Nonerosive Reflux Disease Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Nonerosive Reflux Disease Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Nonerosive Reflux Disease Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Nonerosive Reflux Disease Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Nonerosive Reflux Disease Treatment Revenue by Country
  11. 9.6.1 Europe Nonerosive Reflux Disease Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Nonerosive Reflux Disease Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Nonerosive Reflux Disease Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Nonerosive Reflux Disease Treatment Revenue (2021-2032)
  2. 10.2 China Nonerosive Reflux Disease Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Nonerosive Reflux Disease Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Nonerosive Reflux Disease Treatment Revenue by Type (2027-2032)
  5. 10.3 China Nonerosive Reflux Disease Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Nonerosive Reflux Disease Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Nonerosive Reflux Disease Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Nonerosive Reflux Disease Treatment Revenue by Application (2027-2032)
  9. 10.5 China Nonerosive Reflux Disease Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Nonerosive Reflux Disease Treatment Revenue (2021-2032)
  2. 11.2 Asia Nonerosive Reflux Disease Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Nonerosive Reflux Disease Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Nonerosive Reflux Disease Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Nonerosive Reflux Disease Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Nonerosive Reflux Disease Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Nonerosive Reflux Disease Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Nonerosive Reflux Disease Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Nonerosive Reflux Disease Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Nonerosive Reflux Disease Treatment Revenue by Country
  11. 11.6.1 Asia Nonerosive Reflux Disease Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Nonerosive Reflux Disease Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Nonerosive Reflux Disease Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Nonerosive Reflux Disease Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Nonerosive Reflux Disease Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Nonerosive Reflux Disease Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Nonerosive Reflux Disease Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Nonerosive Reflux Disease Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Nonerosive Reflux Disease Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Nonerosive Reflux Disease Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Nonerosive Reflux Disease Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Nonerosive Reflux Disease Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Nonerosive Reflux Disease Treatment Revenue by Country
  11. 12.6.1 SAMEA Nonerosive Reflux Disease Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Nonerosive Reflux Disease Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Nonerosive Reflux Disease Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst